Abstract:B-Myb, also known as MYB proto-oncogene like 2 (MYBL2), is an important transcription factor implicated in transcription regulation, cell cycle and tumorigenesis. However, the molecular mechanism underlying B-Myb-controlled transactivation in different cell contexts as well as its functional implication in cancers remains elusive. In this study, we have conducted a comprehensive genome-wide analysis of B-Myb binding sites in multiple immortalized or cancer cell lines and identified its critical target genes. The results revealed that B-Myb regulates a common set of core cell cycle genes and cell type-specific genes through collaboration with other important transcription factors (e.g. NFY and MuvB complex) and binding to cell type-invariant promoters and cell type-specific enhancers and super-enhancers. KIF2C, UBE2C and MYC were further validated as B-Myb target genes. Loss-of-function analysis demonstrated that KIF2C knockdown inhibited tumor cell growth both in vitro and in vivo, suppressed cell motility and cell cycle progression, accompanied with defects in microtubule organization and mitosis, strongly suggesting that KIF2C is a critical regulator of cancer cell growth and mitosis, and maintains high cancer cell motility ability and microtubule dynamics. Pan-cancer transcriptomic analysis revealed that the overexpression of both B-Myb and KIF2C presents as independent prognostic markers in various types of cancer. Notably, B-Myb associates with NFYB, binds to target gene promoters, enhancers and super-enhancers, and provokes a cascade of oncogenic gene expression profiles in cancers. Overall, our results highly suggest the critical implication of B-Myb-mediated gene regulation in cancers, and the promising therapeutic and prognostic potentials of B-Myb and KIF2C for cancer diagnosis and treatment.

MYC Binding Near Transcriptional End Sites Regulates Basal Gene Expression, Read-Through Transcription and Intragenic Contacts

MYC2 Regulates the Termination of Jasmonate Signaling via an Autoregulatory Negative Feedback Loop.

MYC Promotes Global Transcription in Part by Controlling P-TEFb Complex Formation Via DNA-binding Independent Inhibition of CDK9 SUMOylation

Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis

Transcriptional regulation by MYC: an emerging new model

Intrinsically Disordered Regions in the Transcription Factor MYC:MAX Modulate DNA Binding via Intramolecular Interactions

Regulation of chromatin architecture by transcription factor binding

MYC protein interactors in gene transcription and cancer

Mnt takes control as key regulator of the myc/max/mxd network

Association with TFIIIC limits MYCN localization in hubs of active promoters and chromatin accumulation of non-phosphorylated RNA Polymerase II

Association with TFIIIC limits MYCN localisation in hubs of active promoters and chromatin accumulation of non-phosphorylated RNA polymerase II

The Regulation of Target Genes by Co-occupancy of Transcription Factors, C-Myc and Mxi1 with Max in the Mouse Cell Line

ETS variant transcription factor 5 and c-Myc cooperate in derepressing the human telomerase gene promoter via composite ETS/E-box motifs

A Positive Feedback Loop Between EBP2 and C-Myc Regulates Rdna Transcription, Cell Proliferation, and Tumorigenesis.

MYC overexpression leads to increased chromatin interactions at super-enhancers and MYC binding sites

Genome-wide binding analysis unveils critical implication of B-Myb-mediated transactivation in cancers

MYC dephosphorylation by the PP1/PNUTS phosphatase complex regulates chromatin binding and protein stability

MYC activates transcriptional enhancers to drive cancer progression

Of Myc and Mnt

Target gene-independent functions of MYC oncoproteins